StreetInsider.com News Articles http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2024, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Sun, 21 Apr 2024 21:53:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif StreetInsider.com News Articles http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday GT20029 China Phase II Trial For AGA Reached Primary Endpoint http://www.streetinsider.com/Press+Releases/GT20029+China+Phase+II+Trial+For+AGA+Reached+Primary+Endpoint/23092493.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/GT20029+China+Phase+II+Trial+For+AGA+Reached+Primary+Endpoint/23092493.html for the full story. http://www.streetinsider.com/Press+Releases/GT20029+China+Phase+II+Trial+For+AGA+Reached+Primary+Endpoint/23092493.html Sun, 21 Apr 2024 21:53:00 -0400 9939 O.48132734 GT20029 China Phase II Trial For AGA Reached Primary Endpoint http://www.streetinsider.com/Press+Releases/GT20029+China+Phase+II+Trial+For+AGA+Reached+Primary+Endpoint/23092493.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/GT20029+China+Phase+II+Trial+For+AGA+Reached+Primary+Endpoint/23092493.html for the full story. http://www.streetinsider.com/Press+Releases/GT20029+China+Phase+II+Trial+For+AGA+Reached+Primary+Endpoint/23092493.html Sun, 21 Apr 2024 21:53:00 -0400 9939 O.48132734 GT20029 China Phase II Trial For AGA Reached Primary Endpoint http://www.streetinsider.com/PRNewswire/GT20029+China+Phase+II+Trial+For+AGA+Reached+Primary+Endpoint/23092493.html Visit StreetInsider.com at http://www.streetinsider.com/PRNewswire/GT20029+China+Phase+II+Trial+For+AGA+Reached+Primary+Endpoint/23092493.html for the full story. http://www.streetinsider.com/PRNewswire/GT20029+China+Phase+II+Trial+For+AGA+Reached+Primary+Endpoint/23092493.html Sun, 21 Apr 2024 21:53:00 -0400 9939 O.48132734 GT20029 China Phase II Trial For AGA Reached Primary Endpoint http://www.streetinsider.com/PRNewswire/GT20029+China+Phase+II+Trial+For+AGA+Reached+Primary+Endpoint/23092493.html Visit StreetInsider.com at http://www.streetinsider.com/PRNewswire/GT20029+China+Phase+II+Trial+For+AGA+Reached+Primary+Endpoint/23092493.html for the full story. http://www.streetinsider.com/PRNewswire/GT20029+China+Phase+II+Trial+For+AGA+Reached+Primary+Endpoint/23092493.html Sun, 21 Apr 2024 21:53:00 -0400 9939 O.48132734 Study of Kintor's c-Myc Degrader Published in Subsidiary Journal of Nature http://www.streetinsider.com/Press+Releases/Study+of+Kintor%26apos%3Bs+c-Myc+Degrader+Published+in+Subsidiary+Journal+of+Nature/22928355.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Study+of+Kintor%26apos%3Bs+c-Myc+Degrader+Published+in+Subsidiary+Journal+of+Nature/22928355.html for the full story. http://www.streetinsider.com/Press+Releases/Study+of+Kintor%26apos%3Bs+c-Myc+Degrader+Published+in+Subsidiary+Journal+of+Nature/22928355.html Thu, 14 Mar 2024 00:22:00 -0400 9939 O.48132734 Study of Kintor's c-Myc Degrader Published in Subsidiary Journal of Nature http://www.streetinsider.com/Press+Releases/Study+of+Kintor%26apos%3Bs+c-Myc+Degrader+Published+in+Subsidiary+Journal+of+Nature/22928355.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Study+of+Kintor%26apos%3Bs+c-Myc+Degrader+Published+in+Subsidiary+Journal+of+Nature/22928355.html for the full story. http://www.streetinsider.com/Press+Releases/Study+of+Kintor%26apos%3Bs+c-Myc+Degrader+Published+in+Subsidiary+Journal+of+Nature/22928355.html Thu, 14 Mar 2024 00:22:00 -0400 9939 O.48132734 Study of Kintor's c-Myc Degrader Published in Subsidiary Journal of Nature http://www.streetinsider.com/PRNewswire/Study+of+Kintor%26apos%3Bs+c-Myc+Degrader+Published+in+Subsidiary+Journal+of+Nature/22928355.html Visit StreetInsider.com at http://www.streetinsider.com/PRNewswire/Study+of+Kintor%26apos%3Bs+c-Myc+Degrader+Published+in+Subsidiary+Journal+of+Nature/22928355.html for the full story. http://www.streetinsider.com/PRNewswire/Study+of+Kintor%26apos%3Bs+c-Myc+Degrader+Published+in+Subsidiary+Journal+of+Nature/22928355.html Thu, 14 Mar 2024 00:22:00 -0400 9939 O.48132734 Study of Kintor's c-Myc Degrader Published in Subsidiary Journal of Nature http://www.streetinsider.com/PRNewswire/Study+of+Kintor%26apos%3Bs+c-Myc+Degrader+Published+in+Subsidiary+Journal+of+Nature/22928355.html Visit StreetInsider.com at http://www.streetinsider.com/PRNewswire/Study+of+Kintor%26apos%3Bs+c-Myc+Degrader+Published+in+Subsidiary+Journal+of+Nature/22928355.html for the full story. http://www.streetinsider.com/PRNewswire/Study+of+Kintor%26apos%3Bs+c-Myc+Degrader+Published+in+Subsidiary+Journal+of+Nature/22928355.html Thu, 14 Mar 2024 00:22:00 -0400 9939 O.48132734 Kintor Pharma Announces the Approval for Phase II Clinical Trial of Hedgehog/SMO Inhibitor GT1708F for Treatment of IPF in China http://www.streetinsider.com/Press+Releases/Kintor+Pharma+Announces+the+Approval+for+Phase+II+Clinical+Trial+of+HedgehogSMO+Inhibitor+GT1708F+for+Treatment+of+IPF+in+China/22259623.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Kintor+Pharma+Announces+the+Approval+for+Phase+II+Clinical+Trial+of+HedgehogSMO+Inhibitor+GT1708F+for+Treatment+of+IPF+in+China/22259623.html for the full story. http://www.streetinsider.com/Press+Releases/Kintor+Pharma+Announces+the+Approval+for+Phase+II+Clinical+Trial+of+HedgehogSMO+Inhibitor+GT1708F+for+Treatment+of+IPF+in+China/22259623.html Wed, 11 Oct 2023 05:20:00 -0400 9939 O.48132734 Kintor Pharma Announces the Approval for Phase II Clinical Trial of Hedgehog/SMO Inhibitor GT1708F for Treatment of IPF in China http://www.streetinsider.com/Press+Releases/Kintor+Pharma+Announces+the+Approval+for+Phase+II+Clinical+Trial+of+HedgehogSMO+Inhibitor+GT1708F+for+Treatment+of+IPF+in+China/22259623.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Kintor+Pharma+Announces+the+Approval+for+Phase+II+Clinical+Trial+of+HedgehogSMO+Inhibitor+GT1708F+for+Treatment+of+IPF+in+China/22259623.html for the full story. http://www.streetinsider.com/Press+Releases/Kintor+Pharma+Announces+the+Approval+for+Phase+II+Clinical+Trial+of+HedgehogSMO+Inhibitor+GT1708F+for+Treatment+of+IPF+in+China/22259623.html Wed, 11 Oct 2023 05:20:00 -0400 9939 O.48132734 Kintor Pharma Announces the Approval for Phase II Clinical Trial of Hedgehog/SMO Inhibitor GT1708F for Treatment of IPF in China http://www.streetinsider.com/PRNewswire/Kintor+Pharma+Announces+the+Approval+for+Phase+II+Clinical+Trial+of+HedgehogSMO+Inhibitor+GT1708F+for+Treatment+of+IPF+in+China/22259623.html Visit StreetInsider.com at http://www.streetinsider.com/PRNewswire/Kintor+Pharma+Announces+the+Approval+for+Phase+II+Clinical+Trial+of+HedgehogSMO+Inhibitor+GT1708F+for+Treatment+of+IPF+in+China/22259623.html for the full story. http://www.streetinsider.com/PRNewswire/Kintor+Pharma+Announces+the+Approval+for+Phase+II+Clinical+Trial+of+HedgehogSMO+Inhibitor+GT1708F+for+Treatment+of+IPF+in+China/22259623.html Wed, 11 Oct 2023 05:20:00 -0400 9939 O.48132734 Kintor Pharma Announces the Approval for Phase II Clinical Trial of Hedgehog/SMO Inhibitor GT1708F for Treatment of IPF in China http://www.streetinsider.com/PRNewswire/Kintor+Pharma+Announces+the+Approval+for+Phase+II+Clinical+Trial+of+HedgehogSMO+Inhibitor+GT1708F+for+Treatment+of+IPF+in+China/22259623.html Visit StreetInsider.com at http://www.streetinsider.com/PRNewswire/Kintor+Pharma+Announces+the+Approval+for+Phase+II+Clinical+Trial+of+HedgehogSMO+Inhibitor+GT1708F+for+Treatment+of+IPF+in+China/22259623.html for the full story. http://www.streetinsider.com/PRNewswire/Kintor+Pharma+Announces+the+Approval+for+Phase+II+Clinical+Trial+of+HedgehogSMO+Inhibitor+GT1708F+for+Treatment+of+IPF+in+China/22259623.html Wed, 11 Oct 2023 05:20:00 -0400 9939 O.48132734 Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China http://www.streetinsider.com/Press+Releases/Kintor+Pharma+Announces+Completion+of+Patient+Enrollment+in+Phase+II+Clinical+Trial+of+GT20029+for+Treatment+of+Androgenetic+Alopecia+in+China/22072058.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Kintor+Pharma+Announces+Completion+of+Patient+Enrollment+in+Phase+II+Clinical+Trial+of+GT20029+for+Treatment+of+Androgenetic+Alopecia+in+China/22072058.html for the full story. http://www.streetinsider.com/Press+Releases/Kintor+Pharma+Announces+Completion+of+Patient+Enrollment+in+Phase+II+Clinical+Trial+of+GT20029+for+Treatment+of+Androgenetic+Alopecia+in+China/22072058.html Tue, 22 Aug 2023 05:13:00 -0400 9939 O.48132734 Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China http://www.streetinsider.com/Press+Releases/Kintor+Pharma+Announces+Completion+of+Patient+Enrollment+in+Phase+II+Clinical+Trial+of+GT20029+for+Treatment+of+Androgenetic+Alopecia+in+China/22072058.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Kintor+Pharma+Announces+Completion+of+Patient+Enrollment+in+Phase+II+Clinical+Trial+of+GT20029+for+Treatment+of+Androgenetic+Alopecia+in+China/22072058.html for the full story. http://www.streetinsider.com/Press+Releases/Kintor+Pharma+Announces+Completion+of+Patient+Enrollment+in+Phase+II+Clinical+Trial+of+GT20029+for+Treatment+of+Androgenetic+Alopecia+in+China/22072058.html Tue, 22 Aug 2023 05:13:00 -0400 9939 O.48132734 Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China http://www.streetinsider.com/PRNewswire/Kintor+Pharma+Announces+Completion+of+Patient+Enrollment+in+Phase+II+Clinical+Trial+of+GT20029+for+Treatment+of+Androgenetic+Alopecia+in+China/22072058.html Visit StreetInsider.com at http://www.streetinsider.com/PRNewswire/Kintor+Pharma+Announces+Completion+of+Patient+Enrollment+in+Phase+II+Clinical+Trial+of+GT20029+for+Treatment+of+Androgenetic+Alopecia+in+China/22072058.html for the full story. http://www.streetinsider.com/PRNewswire/Kintor+Pharma+Announces+Completion+of+Patient+Enrollment+in+Phase+II+Clinical+Trial+of+GT20029+for+Treatment+of+Androgenetic+Alopecia+in+China/22072058.html Tue, 22 Aug 2023 05:13:00 -0400 9939 O.48132734 Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China http://www.streetinsider.com/PRNewswire/Kintor+Pharma+Announces+Completion+of+Patient+Enrollment+in+Phase+II+Clinical+Trial+of+GT20029+for+Treatment+of+Androgenetic+Alopecia+in+China/22072058.html Visit StreetInsider.com at http://www.streetinsider.com/PRNewswire/Kintor+Pharma+Announces+Completion+of+Patient+Enrollment+in+Phase+II+Clinical+Trial+of+GT20029+for+Treatment+of+Androgenetic+Alopecia+in+China/22072058.html for the full story. http://www.streetinsider.com/PRNewswire/Kintor+Pharma+Announces+Completion+of+Patient+Enrollment+in+Phase+II+Clinical+Trial+of+GT20029+for+Treatment+of+Androgenetic+Alopecia+in+China/22072058.html Tue, 22 Aug 2023 05:13:00 -0400 9939 O.48132734 Kintor Pharma Announces Completion of First Patient Enrollment in Long-term Safety Phase III Trial of KX-826 for Treatment of AGA http://www.streetinsider.com/Press+Releases/Kintor+Pharma+Announces+Completion+of+First+Patient+Enrollment+in+Long-term+Safety+Phase+III+Trial+of+KX-826+for+Treatment+of+AGA/21923341.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Kintor+Pharma+Announces+Completion+of+First+Patient+Enrollment+in+Long-term+Safety+Phase+III+Trial+of+KX-826+for+Treatment+of+AGA/21923341.html for the full story. http://www.streetinsider.com/Press+Releases/Kintor+Pharma+Announces+Completion+of+First+Patient+Enrollment+in+Long-term+Safety+Phase+III+Trial+of+KX-826+for+Treatment+of+AGA/21923341.html Wed, 19 Jul 2023 09:03:00 -0400 9939 O.48132734 Kintor Pharma Announces Completion of First Patient Enrollment in Long-term Safety Phase III Trial of KX-826 for Treatment of AGA http://www.streetinsider.com/Press+Releases/Kintor+Pharma+Announces+Completion+of+First+Patient+Enrollment+in+Long-term+Safety+Phase+III+Trial+of+KX-826+for+Treatment+of+AGA/21923341.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Kintor+Pharma+Announces+Completion+of+First+Patient+Enrollment+in+Long-term+Safety+Phase+III+Trial+of+KX-826+for+Treatment+of+AGA/21923341.html for the full story. http://www.streetinsider.com/Press+Releases/Kintor+Pharma+Announces+Completion+of+First+Patient+Enrollment+in+Long-term+Safety+Phase+III+Trial+of+KX-826+for+Treatment+of+AGA/21923341.html Wed, 19 Jul 2023 09:03:00 -0400 9939 O.48132734 Kintor Pharma Announces Completion of First Patient Enrollment in Long-term Safety Phase III Trial of KX-826 for Treatment of AGA http://www.streetinsider.com/PRNewswire/Kintor+Pharma+Announces+Completion+of+First+Patient+Enrollment+in+Long-term+Safety+Phase+III+Trial+of+KX-826+for+Treatment+of+AGA/21923341.html Visit StreetInsider.com at http://www.streetinsider.com/PRNewswire/Kintor+Pharma+Announces+Completion+of+First+Patient+Enrollment+in+Long-term+Safety+Phase+III+Trial+of+KX-826+for+Treatment+of+AGA/21923341.html for the full story. http://www.streetinsider.com/PRNewswire/Kintor+Pharma+Announces+Completion+of+First+Patient+Enrollment+in+Long-term+Safety+Phase+III+Trial+of+KX-826+for+Treatment+of+AGA/21923341.html Wed, 19 Jul 2023 09:03:00 -0400 9939 O.48132734 Kintor Pharma Announces Completion of First Patient Enrollment in Long-term Safety Phase III Trial of KX-826 for Treatment of AGA http://www.streetinsider.com/PRNewswire/Kintor+Pharma+Announces+Completion+of+First+Patient+Enrollment+in+Long-term+Safety+Phase+III+Trial+of+KX-826+for+Treatment+of+AGA/21923341.html Visit StreetInsider.com at http://www.streetinsider.com/PRNewswire/Kintor+Pharma+Announces+Completion+of+First+Patient+Enrollment+in+Long-term+Safety+Phase+III+Trial+of+KX-826+for+Treatment+of+AGA/21923341.html for the full story. http://www.streetinsider.com/PRNewswire/Kintor+Pharma+Announces+Completion+of+First+Patient+Enrollment+in+Long-term+Safety+Phase+III+Trial+of+KX-826+for+Treatment+of+AGA/21923341.html Wed, 19 Jul 2023 09:03:00 -0400 9939 O.48132734 Kintor Pharma Announces Successful Completion of Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US http://www.streetinsider.com/Press+Releases/Kintor+Pharma+Announces+Successful+Completion+of+Phase+II+Clinical+Trial+of+KX-826+for+Treatment+of+Androgenetic+Alopecia+in+the+US/21650328.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Kintor+Pharma+Announces+Successful+Completion+of+Phase+II+Clinical+Trial+of+KX-826+for+Treatment+of+Androgenetic+Alopecia+in+the+US/21650328.html for the full story. http://www.streetinsider.com/Press+Releases/Kintor+Pharma+Announces+Successful+Completion+of+Phase+II+Clinical+Trial+of+KX-826+for+Treatment+of+Androgenetic+Alopecia+in+the+US/21650328.html Thu, 11 May 2023 11:30:00 -0400 9939 O.48132734 Kintor Pharma Announces Successful Completion of Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US http://www.streetinsider.com/Press+Releases/Kintor+Pharma+Announces+Successful+Completion+of+Phase+II+Clinical+Trial+of+KX-826+for+Treatment+of+Androgenetic+Alopecia+in+the+US/21650328.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Kintor+Pharma+Announces+Successful+Completion+of+Phase+II+Clinical+Trial+of+KX-826+for+Treatment+of+Androgenetic+Alopecia+in+the+US/21650328.html for the full story. http://www.streetinsider.com/Press+Releases/Kintor+Pharma+Announces+Successful+Completion+of+Phase+II+Clinical+Trial+of+KX-826+for+Treatment+of+Androgenetic+Alopecia+in+the+US/21650328.html Thu, 11 May 2023 11:30:00 -0400 9939 O.48132734 Kintor Pharma Announces Successful Completion of Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US http://www.streetinsider.com/PRNewswire/Kintor+Pharma+Announces+Successful+Completion+of+Phase+II+Clinical+Trial+of+KX-826+for+Treatment+of+Androgenetic+Alopecia+in+the+US/21650328.html Visit StreetInsider.com at http://www.streetinsider.com/PRNewswire/Kintor+Pharma+Announces+Successful+Completion+of+Phase+II+Clinical+Trial+of+KX-826+for+Treatment+of+Androgenetic+Alopecia+in+the+US/21650328.html for the full story. http://www.streetinsider.com/PRNewswire/Kintor+Pharma+Announces+Successful+Completion+of+Phase+II+Clinical+Trial+of+KX-826+for+Treatment+of+Androgenetic+Alopecia+in+the+US/21650328.html Thu, 11 May 2023 11:30:00 -0400 9939 O.48132734 Kintor Pharma Announces Successful Completion of Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US http://www.streetinsider.com/PRNewswire/Kintor+Pharma+Announces+Successful+Completion+of+Phase+II+Clinical+Trial+of+KX-826+for+Treatment+of+Androgenetic+Alopecia+in+the+US/21650328.html Visit StreetInsider.com at http://www.streetinsider.com/PRNewswire/Kintor+Pharma+Announces+Successful+Completion+of+Phase+II+Clinical+Trial+of+KX-826+for+Treatment+of+Androgenetic+Alopecia+in+the+US/21650328.html for the full story. http://www.streetinsider.com/PRNewswire/Kintor+Pharma+Announces+Successful+Completion+of+Phase+II+Clinical+Trial+of+KX-826+for+Treatment+of+Androgenetic+Alopecia+in+the+US/21650328.html Thu, 11 May 2023 11:30:00 -0400 9939 O.48132734 Kintor Pharma Announces 2022 Annual Results and Recent Business Progress http://www.streetinsider.com/Press+Releases/Kintor+Pharma+Announces+2022+Annual+Results+and+Recent+Business+Progress/21441936.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Kintor+Pharma+Announces+2022+Annual+Results+and+Recent+Business+Progress/21441936.html for the full story. http://www.streetinsider.com/Press+Releases/Kintor+Pharma+Announces+2022+Annual+Results+and+Recent+Business+Progress/21441936.html Thu, 30 Mar 2023 12:33:00 -0400 9939 O.48132734